{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:32:01Z","timestamp":1763389921612,"version":"3.40.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82373956"],"award-info":[{"award-number":["No. 82373956"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovation Capability Support Program in Shaanxi province of China","award":["No. 2023-CX-PT-43"],"award-info":[{"award-number":["No. 2023-CX-PT-43"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10096-025-05063-2","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T19:08:36Z","timestamp":1739646516000},"page":"973-983","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Whether to continue combining carbapenems to treat carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia in critically ill patients: a retrospective efficacy and safety analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Cheng","family":"Shiqi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Chuhui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhang","family":"Yijing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu","family":"Yulan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Jiaojiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Keyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi","family":"Qindong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeng","family":"Xiaoyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Yalin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"5063_CR1","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","volume":"404","author":"M Naghavi","year":"2024","unstructured":"Naghavi M, Vollset SE, Ikuta KS et al (2024) Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050. Lancet 404:1199\u20131226. https:\/\/doi.org\/10.1016\/S0140-6736(24)01867-1","journal-title":"Lancet"},{"key":"5063_CR2","unstructured":"World Health Organization (2024) WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. https:\/\/www.who.int\/publications\/i\/item\/9789240093461. Accessed 11 Nov 2024"},{"key":"5063_CR3","doi-asserted-by":"publisher","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ (2023) Infectious Diseases Society of America 2023 Guidance on the treatment of Antimicrobial resistant gram-negative infections. https:\/\/doi.org\/10.1093\/cid\/ciad428. Clin Infect Dis ciad428","DOI":"10.1093\/cid\/ciad428"},{"key":"5063_CR4","unstructured":"CHINET (2024) CHINET 2023 Results of Bacterial Resistance Surveillance. https:\/\/www.chinets.com\/Data\/AntibioticDrugFast. Accessed 11 Nov 2024"},{"key":"5063_CR5","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1093\/cid\/ciad094","volume":"76","author":"RK Shields","year":"2023","unstructured":"Shields RK, Paterson DL, Tamma PD (2023) Navigating available treatment options for Carbapenem-Resistant Acinetobacter baumannii-Calcoaceticus Complex infections. Clin Infect Dis 76:S179\u2013S193. https:\/\/doi.org\/10.1093\/cid\/ciad094","journal-title":"Clin Infect Dis"},{"key":"5063_CR6","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA (2024) Infectious Diseases Society of America 2024 Guidance on the treatment of antimicrobial-resistant gram-negative infections. https:\/\/doi.org\/10.1093\/cid\/ciae403. Clin Infect Dis ciae403","DOI":"10.1093\/cid\/ciae403"},{"key":"5063_CR7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T et al (2022) European Society of Clinical Microbiology and Infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect 28:521\u2013547. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025","journal-title":"Clin Microbiol Infect"},{"key":"5063_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jmii.2022.02.001","volume":"55","author":"CL Sy","year":"2022","unstructured":"Sy CL, Chen PY, Cheng CW et al (2022) Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms. J Microbiol Immunol Infect 55:359\u2013386. https:\/\/doi.org\/10.1016\/j.jmii.2022.02.001","journal-title":"J Microbiol Immunol Infect"},{"key":"5063_CR9","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jmii.2023.01.017","volume":"56","author":"M Zeng","year":"2023","unstructured":"Zeng M, Xia J, Zong Z et al (2023) Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli. J Microbiol Immunol Infect 56:653\u2013671. https:\/\/doi.org\/10.1016\/j.jmii.2023.01.017","journal-title":"J Microbiol Immunol Infect"},{"key":"5063_CR10","doi-asserted-by":"publisher","first-page":"1395260","DOI":"10.3389\/fcimb.2024.1395260","volume":"14","author":"S Zhang","year":"2024","unstructured":"Zhang S, Di L, Qi Y, Qian X, Wang S (2024) Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii. Front Cell Infect Microbiol 14:1395260. https:\/\/doi.org\/10.3389\/fcimb.2024.1395260","journal-title":"Front Cell Infect Microbiol"},{"key":"5063_CR11","doi-asserted-by":"publisher","first-page":"e01680","DOI":"10.1128\/AAC.01680-20","volume":"65","author":"M Beganovic","year":"2021","unstructured":"Beganovic M, Daffinee KE, Luther MK, LaPlante KL (2021) Minocycline alone and in combination with polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 65:e01680. https:\/\/doi.org\/10.1128\/AAC.01680-20","journal-title":"Antimicrob Agents Chemother"},{"key":"5063_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jhin.2024.04.013","volume":"149","author":"H Diao","year":"2024","unstructured":"Diao H, Lu G, Zhang Y, Wang Z, Liu X, Ma Q, Yu H, Li Y (2024) Risk factors for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii infection of patients admitted in intensive care unit: a systematic review and meta-analysis. J Hosp Infect 149:77\u201387. https:\/\/doi.org\/10.1016\/j.jhin.2024.04.013","journal-title":"J Hosp Infect"},{"key":"5063_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/JS9.0000000000000153","volume":"109","author":"M Manjusha","year":"2023","unstructured":"Manjusha M, Yasasve M, Saravanan M, Belete MA (2023) Carbapenem-resistant Acinetobacter baumannii healthcare-associated infections: antimicrobial resistance and its spread as a global threat. Int J Surg (London England) 109:526. https:\/\/doi.org\/10.1097\/JS9.0000000000000153","journal-title":"Int J Surg (London England)"},{"key":"5063_CR14","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1007\/s10096-024-04936-2","volume":"43","author":"M Peghin","year":"2024","unstructured":"Peghin M, Givone F, de Martino M, Ali RW, Graziano E, Isola M, Grossi PA (2024) Risk factors for infection after carbapenem-resistant Acinetobacter baumannii colonization. Eur J Clin Microbiol Infect Dis 43:2191\u20132199. https:\/\/doi.org\/10.1007\/s10096-024-04936-2","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5063_CR15","doi-asserted-by":"publisher","first-page":"S166","DOI":"10.1093\/cid\/ciad109","volume":"76","author":"M Castanheira","year":"2023","unstructured":"Castanheira M, Mendes RE, Gales AC (2023) Global Epidemiology and mechanisms of resistance of Acinetobacter baumannii-Calcoaceticus Complex. Clin Infect Dis 76:S166\u2013S178. https:\/\/doi.org\/10.1093\/cid\/ciad109","journal-title":"Clin Infect Dis"},{"key":"5063_CR16","doi-asserted-by":"publisher","first-page":"e02260","DOI":"10.1128\/mbio.02260-23","volume":"14","author":"C M\u00fcller","year":"2023","unstructured":"M\u00fcller C, Reuter S, Wille J, Xanthopoulou K, Stefanik D, Grundmann H, Higgins PG, Seifert H (2023) A global view on carbapenem-resistant Acinetobacter baumannii. mBio 14:e02260. https:\/\/doi.org\/10.1128\/mbio.02260-23","journal-title":"mBio"},{"key":"5063_CR17","doi-asserted-by":"publisher","first-page":"6814","DOI":"10.3390\/ijms25136814","volume":"25","author":"A Marino","year":"2024","unstructured":"Marino A, Augello E, Stracquadanio S, Bellanca CM, Cosentino F, Spampinato S, Cantarella G, Bernardini R, Stefani S, Cacopardo B, Nunnari G (2024) Unveiling the secrets of Acinetobacter baumannii: resistance, current treatments, and future innovations. Int J Mol Sci 25:6814. https:\/\/doi.org\/10.3390\/ijms25136814","journal-title":"Int J Mol Sci"},{"key":"5063_CR18","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.jmii.2023.04.004","volume":"56","author":"H-H Kao","year":"2023","unstructured":"Kao H-H, Peng C-K, Sheu C-C, Lin Y-C, Chan M-C, Wang S-H, Chen C-M, Shen Y-C, Zheng Z-R, Lin Y-T, Hsu H-S, Feng J-Y, Yang K-Y (2023) Mortality and ventilator dependence in critically ill patients with ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. J Microb Immunol Infect 56:822\u2013832. https:\/\/doi.org\/10.1016\/j.jmii.2023.04.004","journal-title":"J Microb Immunol Infect"},{"key":"5063_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3760\/cma.j.issn.1001-0939.2018.04.006","volume":"41","author":"Society of Respiratory Medicine CIDG","year":"2018","unstructured":"Society of Respiratory Medicine CIDG (2018) Guidelines for diagnosis and treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in adults in China. Chin J Tubere Respir Dis 41:255\u2013280. https:\/\/doi.org\/10.3760\/cma.j.issn.1001-0939.2018.04.006","journal-title":"Chin J Tubere Respir Dis"},{"key":"5063_CR20","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M et al (2016) Management of adults with hospital-acquired and ventilator-associated Pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63:e61\u2013e111. https:\/\/doi.org\/10.1093\/cid\/ciw353","journal-title":"Clin Infect Dis"},{"key":"5063_CR21","doi-asserted-by":"publisher","first-page":"107044","DOI":"10.1016\/j.ijantimicag.2023.107044","volume":"63","author":"SH Wang","year":"2024","unstructured":"Wang SH, Yang KY, Sheu CC et al (2024) Efficacy of combination therapy with standard-dose carbapenem for treating nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii in intensive care units: a multicentre retrospective propensity score-matched study. Int J Antimicrob Agents 63:107044. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107044","journal-title":"Int J Antimicrob Agents"},{"key":"5063_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01864-19","author":"MP Weinstein","year":"2020","unstructured":"Weinstein MP, LewisII JS (2020) The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial susceptibility testing: background, Organization, functions, and processes. J Clin Microbiol. https:\/\/doi.org\/10.1128\/jcm.01864-19","journal-title":"J Clin Microbiol"},{"key":"5063_CR23","doi-asserted-by":"publisher","unstructured":"Humphries R, Bobenchik AM, Hindler JA, Schuetz AN Overview of changes to the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, M100, 31st Edition. J Clin Microbiol 59:e00213\u2013e00221. https:\/\/doi.org\/10.1128\/JCM.00213-21","DOI":"10.1128\/JCM.00213-21"},{"key":"5063_CR24","unstructured":"eucast Clinical breakpoints and dosing of antibiotics. https:\/\/www.eucast.org\/clinical_breakpoints. Accessed 26 Nov 2024"},{"key":"5063_CR25","unstructured":"Diagnosis evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)| Critical Care| Full Text. https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/cc11454. Accessed 26 Sep 2024"},{"key":"5063_CR26","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.13286\/j.cnki.chinhosppharmacyj.2018.20.09","volume":"38","author":"Y Liu","year":"2018","unstructured":"Liu Y, Wu H, Xiao Y, Wang F (2018) Measurement of meropenem concentration in human plasma by HPLC combining with truncation technique and its technical assessment. Chin J Hosp Pharm 38:2128\u20132132. https:\/\/doi.org\/10.13286\/j.cnki.chinhosppharmacyj.2018.20.09","journal-title":"Chin J Hosp Pharm"},{"key":"5063_CR27","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.6039\/j.issn.1001-0408.2024.16.15","volume":"35","author":"Y Chen","year":"2024","unstructured":"Chen Y, Sun D, Han W, Wang Q, Zhang H (2024) Establishment and clinical application of imipenem measurement method in patients with severe infection. China Pharm 35:2023\u20132026. https:\/\/doi.org\/10.6039\/j.issn.1001-0408.2024.16.15","journal-title":"China Pharm"},{"key":"5063_CR28","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1093\/jac\/dkac245","volume":"77","author":"R Rohani","year":"2022","unstructured":"Rohani R, Scheetz MH, Donnelly HK, Donayre A, Kang M, Diaz E, Dedicatoria K, Hauser AR, Ozer EA, Nozick S, Qi C, Pawlowski AE, Neely MN, Misharin AV, Wunderink RG, Rhodes NJ, NU SCRIPT Study investigators (2022) Individual target pharmacokinetic\/pharmacodynamic attainment rates among meropenem-treated patients admitted to the ICU with hospital-acquired pneumonia. J Antimicrob Chemother 77:2956\u20132959. https:\/\/doi.org\/10.1093\/jac\/dkac245","journal-title":"J Antimicrob Chemother"},{"key":"5063_CR29","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar J-WC, Bassetti M et al (2020) Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position Paper#. Intensive Care Med 46:1127. https:\/\/doi.org\/10.1007\/s00134-020-06050-1","journal-title":"Intensive Care Med"},{"key":"5063_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3390\/antibiotics13020137","volume":"13","author":"M Wantanatavatod","year":"2024","unstructured":"Wantanatavatod M, Wongkulab P (2024) Clinical efficacy of Sitafloxacin\u2013colistin\u2013meropenem and colistin\u2013meropenem in patients with carbapenem-resistant and multidrug-resistant Acinetobacter baumannii Hospital-Acquired Pneumonia (HAP)\/Ventilator-Associated Pneumonia (VAP) in one Super-tertiary Hospital in Bangkok, Thailand: a Randomized Controlled Trial. Antibiotics 13:137. https:\/\/doi.org\/10.3390\/antibiotics13020137","journal-title":"Antibiotics"},{"key":"5063_CR31","doi-asserted-by":"publisher","first-page":"106880","DOI":"10.1016\/j.ijantimicag.2023.106880","volume":"62","author":"L Qiao","year":"2023","unstructured":"Qiao L, Zuo W, Yang Y, Liu X, Wang Q, Yu J, Wu J, Xu T, Jiang J, Zhang B, Long Y (2023) Clinical outcomes and safety of intravenous polymyxin B-based treatment in critically ill patients with carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia. Int J Antimicrob Agents 62:106880. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106880","journal-title":"Int J Antimicrob Agents"},{"key":"5063_CR32","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ijantimicag.2012.12.014","volume":"41","author":"J Ji","year":"2013","unstructured":"Ji J, Du X, Chen Y, Fu Y, Wang H, Yu Y (2013) In vitro activity of sulbactam in combination with imipenem, meropenem, panipenem or cefoperazone against clinical isolates of Acinetobacter baumannii. Int J Antimicrob Agents 41:400\u2013401. https:\/\/doi.org\/10.1016\/j.ijantimicag.2012.12.014","journal-title":"Int J Antimicrob Agents"},{"key":"5063_CR33","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/antibiotics10070880","volume":"10","author":"JC Abdul-Mutakabbir","year":"2021","unstructured":"Abdul-Mutakabbir JC, Yim J, Nguyen L, Maassen PT, Stamper K, Shiekh Z, Kebriaei R, Shields RK, Castanheira M, Kaye KS, Rybak MJ (2021) In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant Acinetobacter baumannii. Antibiotics 10:880. https:\/\/doi.org\/10.3390\/antibiotics10070880","journal-title":"Antibiotics"},{"key":"5063_CR34","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/j.1469-0691.2008.02101.x","volume":"14","author":"JN Kattan","year":"2008","unstructured":"Kattan JN, Villegas MV, Quinn JP (2008) New developments in carbapenems. Clin Microbiol Infect 14:1102\u20131111. https:\/\/doi.org\/10.1111\/j.1469-0691.2008.02101.x","journal-title":"Clin Microbiol Infect"},{"key":"5063_CR35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jinf.2019.05.017","volume":"79","author":"A Russo","year":"2019","unstructured":"Russo A, Bassetti M, Ceccarelli G et al (2019) Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: clinical features, therapy and outcome from a multicenter study. J Infect 79:130\u2013138. https:\/\/doi.org\/10.1016\/j.jinf.2019.05.017","journal-title":"J Infect"},{"key":"5063_CR36","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"R Guilhaumou","year":"2019","unstructured":"Guilhaumou R, Benaboud S, Bennis Y et al (2019) Optimization of the treatment with beta-lactam antibiotics in critically ill patients\u2014guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise De Pharmacologie et Th\u00e9rapeutique\u2014SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation\u2014SFAR). Crit Care 23:104. https:\/\/doi.org\/10.1186\/s13054-019-2378-9","journal-title":"Crit Care"},{"key":"5063_CR37","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M et al (2014) DALI: defining antibiotic levels in Intensive Care Unit patients: are current \u03b2-Lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072\u20131083. https:\/\/doi.org\/10.1093\/cid\/ciu027","journal-title":"Clin Infect Dis"},{"key":"5063_CR38","doi-asserted-by":"publisher","unstructured":"Kaye KS, Marchaim D, Thamlikitkul V et al (2022) Colistin Monotherapy versus Combination Therapy for Carbapenem-resistant organisms. NEJM Evid 2(1). https:\/\/doi.org\/10.1056\/evidoa2200131","DOI":"10.1056\/evidoa2200131"},{"key":"5063_CR39","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","volume":"18","author":"M Paul","year":"2018","unstructured":"Paul M, Daikos GL, Durante-Mangoni E et al (2018) Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis 18:391\u2013400. https:\/\/doi.org\/10.1016\/S1473-3099(18)30099-9","journal-title":"Lancet Infect Dis"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05063-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05063-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05063-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T17:16:08Z","timestamp":1743268568000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05063-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["5063"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05063-2","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was ethically approved by the Ethics Committee of the First Affiliated Hospital of Xi\u2019an Jiaotong University (XJTU1AF2024LSYY-250). On account of the retrospective design and anonymous nature, the Ethics Committee waived the need for patients to sign informed consent. This study adhered to the tenets of the Declaration of Helsinki and the privacy of patient information was adequately protected.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}